Dr. Huaqing Wang: Primary Mediastinal B-Cell Lymphoma (PMBCL) Benefits More Significantly from Axi-Cel Treatment

Dr. Huaqing Wang: Primary Mediastinal B-Cell Lymphoma (PMBCL) Benefits More Significantly from Axi-Cel Treatment

From June 8th to 11th, 2023, the 28th European Hematology Association Congress (EHA) will take place in Frankfurt, Germany, in both online and offline formats, organized by the European Hematology Society. As the largest international conference in the field of European hematology, the EHA Congress will cover various scientific topics, clinical and basic research, benign and malignant hematology, and discuss the latest developments in the field of hematology.
Dr. Hui Wang: A Simple and Rapid Multi-Parameter Flow Cytometry Approach for the Diagnosis and Screening of Malignant Tumors and Related Diseases

Dr. Hui Wang: A Simple and Rapid Multi-Parameter Flow Cytometry Approach for the Diagnosis and Screening of Malignant Tumors and Related Diseases

From June 8 to 12, 2023, the 28th European Hematology Association (EHA) Congress will be held in Frankfurt, Germany, bringing together experts and scholars from around the world to present exciting advances in research. In the field of hematology testing, multi-parameter flow cytometry (MFC) is an important clinical diagnostic method, and the development of fast, simple, and efficient protocols is essential for this technology. A real-world study (P588) conducted by Dr.  Hui Wang's team from Hebei Yanda Ludaopei Hospital and Beijing Ludaopei Hospital has been selected for presentation at EHA.
Dr. Daobin Zhou’s Team: Zanubrutinib combined with R-CHOP regimen demonstrates efficacy and safety in primary treatment of Intravascular Large B-Cell Lymphoma

Dr. Daobin Zhou’s Team: Zanubrutinib combined with R-CHOP regimen demonstrates efficacy and safety in primary treatment of Intravascular Large B-Cell Lymphoma

Intravascular Large B-Cell Lymphoma (IVLBCL) is a subtype of large B-cell lymphoma, characterized by large tumor B-cells aggregating inside blood vessels. This disease is extremely rare and highly malignant, often involving the central nervous system, lungs, and skin. Its prognosis is poor and clinical treatment challenging. At the recently concluded 28th European Hematology Association (EHA) Annual Meeting, a study (Abstract Number: P1185) from Dr. Daobin Zhou's team at Peking Union Medical College Hospital was selected. This study evaluated the efficacy and safety of the Zanubrutinib combined with R-CHOP regimen in treating initial IVLBCL, attracting widespread attention. To further understand this study, the Oncolgy Fronter invited Dr. Zhou for a detailed interpretation and analysis, summarized as follows:
Interview with Dr. Melissa L. Johnson at WCLC 2023

Interview with Dr. Melissa L. Johnson at WCLC 2023

The 2023 World Conference on Lung Cancer (WCLC), organized by the International Association for the Study of Lung Cancer (IASLC), took place in Singapore from September 9-12. Dr. Melissa L. Johnson from Northwestern University's Feinberg School of Medicine presented pivotal findings on antibody-drug conjugates (ADC) for treating small cell lung cancer (SCLC). We had the privilege to interview Dr. Johnson during the conference.
SGBCC 2023 Expert Voting: Surgical Treatment

SGBCC 2023 Expert Voting: Surgical Treatment

The 18th St. Gallen International Breast Cancer Conference (SGBCC 2023) took place in Vienna, the "City of Music," from March 15th to 18th, 2023. SGBCC gathered breast cancer opinion leaders from around the world to discuss and vote on the latest and most controversial topics in early breast cancer diagnosis and treatment, culminating in the biennial St. Gallen International Expert Consensus on Early Breast Cancer. On the final day of the conference, the expert voting session took center stage. Oncology Frontier has  compiled  the following summary of the expert votes on surgical treatment.
2023 SGBCC Expert Voting: Early Treatment Decisions for Triple-Negative Breast Cancer

2023 SGBCC Expert Voting: Early Treatment Decisions for Triple-Negative Breast Cancer

The 18th St. Gallen International Breast Cancer Conference (SGBCC 2023) was held in Vienna, the "City of Music," from March 15 to 18, 2023. SGBCC brought together breast cancer opinion leaders from around the world to discuss and vote on the most cutting-edge and controversial topics in the diagnosis and treatment of early-stage breast cancer. This resulted in the updated St. Gallen International Expert Consensus on Early Breast Cancer every two years.
SGBCC International Dialogue | Dr. JianZhang  Discusses with Dr. Harbeck: Is Chemotherapy Necessary for ER+/HER2- Breast Cancer Patients with Low Genetic Risk but High Clinical Risk?

SGBCC International Dialogue | Dr. JianZhang  Discusses with Dr. Harbeck: Is Chemotherapy Necessary for ER+/HER2- Breast Cancer Patients with Low Genetic Risk but High Clinical Risk?

The 18th St. Gallen International Breast Cancer Conference (SG-BCC 2023) was held in Vienna, the "City of Music," from March 15 to 18, 2023. Breast cancer experts from around the world gathered at this conference to discuss the most cutting-edge and controversial topics in the diagnosis and treatment of early-stage breast cancer, leading to the formation of the updated St. Gallen International Expert Consensus on Early Breast Cancer every two years. Oncology Frontier invited Dr. Jian Zhang from Fudan University Affiliated Cancer Hospital to have an in-depth discussion with Dr. Nadia Harbeck from the University of Munich on the topic of whether chemotherapy is needed for patients with low genetic risk but high clinical risk (ER+/HER2-) breast cancer.
SGBCC 2023 | Academician  BingheXu: Breast Cancer Treatment and Research – An Asian Perspective

SGBCC 2023 | Academician  BingheXu: Breast Cancer Treatment and Research – An Asian Perspective

The 18th St.Gallen International Breast Cancer Conference (SG-BCC 2023) was held in Vienna, the "City of Music," from March 15 to 18, 2023. Academician Binghe Xu  from the Cancer Hospital of the Chinese Academy of Medical Sciences delivered a presentation titled "Breast Cancer Treatment and Research - An Asian Perspective" during the "Session 10: Global Perspective on Breast Cancer Treatment." After his presentation, Academician Binghe Xu  had an interview with Oncology Frontier to discuss related content.
SGBCC  International Dialogue|Dr. LiZhu & Dr. Giuseppe Curigliano Discuss the Need for Adjuvant Therapy After Achieving pCR in Neoadjuvant Treatment

SGBCC  International Dialogue|Dr. LiZhu & Dr. Giuseppe Curigliano Discuss the Need for Adjuvant Therapy After Achieving pCR in Neoadjuvant Treatment

Neoadjuvant therapy has become an integral part of breast cancer treatment, with its increasing application in clinical practice. However, improving the effectiveness of neoadjuvant therapy and optimizing subsequent treatment strategies is a complex issue to consider. At the 18th St.Gallen Breast Cancer Conference (SGBCC 2023), a debate titled "If you achieve pCR after neoadjuvant, do you need adjuvant therapy?" drew global expert attention. Oncology Frontier had  invited Dr. Li Zhu from Shanghai Jiao Tong University School of Medicine, First People's Hospital, and Dr. Giuseppe Curigliano from the University of Milan School of Medicine to engage in an in-depth discussion on this topic.